Table 2. Results of subgroup meta-analysis of different tumor types reported.
| Tumor types | OS | DFS | PFS/RFS | DSS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No./case | HR(95%CI) | I2 (%) | No./case | HR(95%CI) | I2 (%) | No./case | HR(95%CI) | I2 (%) | No./case | HR(95%CI) | I2 (%) | |
| Colorectal cancer | 4/598 | 2.96(1.45-6.03) | 59.9 | 1/247 | 2.64(1.49-4.66) | - | ||||||
| Neuroblastoma | 1/66 | 1.49(0.92-2.40) | - | 1/66 | 3.59(1.02-12.64) | - | ||||||
| Ovarian cancer | 3/581 | 1.25(1.07-1.46) | 11.3 | 1/211 | 1.23(1.02-1.49) | - | 3/465 | 1.85(1.34-2.56) | 0 | |||
| Neuroendocrine tumor | 1/55 | 6.11(1.73-21.66) | - | 1/55 | 3.0(1.14-7.89) | - | ||||||
| GIST | 3/340 | 1.85(1.31-2.61) | 0 | 1/112 | 0.93(0.45-1.93) | - | 2/120 | 4.50(1.61-12.59) | 0 | |||
| Breast cancer | 3/316 | 2.23(0.94-5.30) | 48.3 | 2/219 | 1.32(0.59-2.96) | 18.9 | ||||||
| Cholangiocarcinoma | 1/75 | 2.17(1.16-4.06) | - | 1/75 | 1.38(0.64-3.0) | - | ||||||
| PDAC | 3/311 | 0.96(0.42-2.21) | 85.5 | |||||||||
| Gallbladder cancer | 1/69 | 1.77(0.67-4.65) | - | 1/69 | 3.50(1.15-10.69) | - | ||||||
| Renal cell cancer | 1/282 | 1.80(1.13-2.88) | - | 2/103 | 1.33(0.19-9.09) | 56.7 | ||||||
| NSCLC | 1/472 | 1.31(1.01-1.70) | - | 1/472 | 1.34(1.04-1.73) | - | ||||||
| Hepatocellular cancer | 1/130 | 3.27(1.29-8.30) | - | 1/130 | 2.28(1.04-5.0) | - | ||||||
| Endometrial cancer | 6/4100 | 3.23(1.86-5.60) | 86.2 | 3/2302 | 4.44(1.86-10.6) | 88.6 | 4/879 | 3.93(0.90-17.26) | 89.7 | 1/103 | 4.91(1.68-14.34) | - |
| Vulvar cancer | 1/348 | 1.58(1.08-2.32) | - | 1/348 | 1.7(0.97-2.97) | - | ||||||
| Total | 30/7743 | 2.06(1.65-2.57) | 81.8 | 13/3267 | 2.42(1.40-4.19) | 89.5 | 11/2011 | 2.07(1.41-3.05) | 73 | 3/698 | 2.45(1.48-4.05) | 38.6 |
Overall HR (95%CI) was shown. No. /case refers to number of studies/patients included. Abbreviations: GIST, gastrointestinal Stromal Tumor; PDAC, pancreatic ductal adenocarcinoma; NSCLC, non-small cell lung cancer.